Locations
Palo Alto, CA, USA · Tel Aviv-Yafo, Israel
industry
Biotechnology · DeepTech · Food · Health
Size
11-50 employees
Stage
Series B
founded in
2016
Ukko is a biotech company focused on improving the lives of millions suffering from food allergies and sensitivities. Utilizing a computational protein design platform, Ukko develops innovative therapeutics that modulate the immune system of allergic patients without triggering allergic reactions. The company is creating a clinically validated map of molecular interactions between allergens and the immune system, which allows for the design of new allergen versions that re-educate the immune system to tolerate these allergens. This unique approach positions Ukko as a leader in the food allergy therapeutics market, addressing a significant healthcare challenge with a potential market impact of $25 billion annually.
Something looks off?